# Respiratory Syncytial Virus (RSV) FDA approvals and PDUFA dates

Canonical: https://sec-api.dev/indications/respiratory-syncytial-virus-rsv

> 6 upcoming FDA catalysts in respiratory Syncytial Virus (RSV): rsvpref (PFE) on Jan to Apr 2027 (topline data readout); rsvpref (PFE) on January 2027 (primary completion); rsvpref vaccine (PFE) on Feb to May 2028 (topline data readout); rsvpref vaccine (PFE) on February 2028 (primary completion); and 2 more.

Data as of November 16, 2026 (snapshot 20261116T222116Z). Every date quotes the SEC filing or FDA page it came from. Date precision: exact day, quarter only, month only.

**Free:** every drug page and the next 30 days of the FDA calendar, no account. Calendar API, alerts when a date moves, and full history: https://sec-api.dev/pricing . Free API key: https://sec-api.dev/sign-up?ref=ai-claudebot

## Catalysts

| Date | Event | Ticker | Indication | Status | Source sentence |
| --- | --- | --- | --- | --- | --- |
| September 30, 2025 | [Respiratory syncytial virus prefusion f subunit vaccine primary completion](https://sec-api.dev/pdufa/respiratory-syncytial-virus-prefusion-f-subunit-vaccine) | PFE | Respiratory Syncytial Virus (RSV) | completed | "NCT06890416 (A Study to Evaluate the Safety and Immunogenicity of RSVpreF Coadministered With Herpes Zoster Vaccine in Adults): Overall Status COMPLETED; Phase PHASE3; Primary Completion 2025-09-30 (ACTUAL); Lead Sponsor Pfizer." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06890416)) |
| August 25, 2026 | [Rsvpref primary completion](https://sec-api.dev/pdufa/rsvpref) | PFE | Respiratory Syncytial Virus (RSV) | completed | "NCT07543380 (A Study to Learn Safety and Immune Response to Study Vaccine -RSVpreF in Adults at High Risk of Severe RSV Disease.): Overall Status COMPLETED; Phase PHASE3; Primary Completion 2026-08-25 (ACTUAL); Lead Sponsor Pfizer." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07543380)) |
| Aug to Nov 2026 | [Rsvpref topline data readout](https://sec-api.dev/pdufa/rsvpref) | PFE | Respiratory Syncytial Virus (RSV) | scheduled | "NCT07543380 (A Study to Learn Safety and Immune Response to Study Vaccine -RSVpreF in Adults at High Risk of Severe RSV Disease.): Overall Status COMPLETED; Phase PHASE3; Primary Completion 2026-08-25 (ACTUAL); Lead Sponsor Pfizer." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07543380)) |
| Jan to Apr 2027 | [Rsvpref topline data readout](https://sec-api.dev/pdufa/rsvpref) | PFE | Respiratory Syncytial Virus (RSV) | scheduled | "NCT07653100 (A Phase 3 Study in India to Describe the Safety and Immunogenicity of RSVpreF): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2027-01-25 (ESTIMATED); Lead Sponsor Pfizer." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07653100)) |
| January 2027 | [Rsvpref primary completion](https://sec-api.dev/pdufa/rsvpref) | PFE | Respiratory Syncytial Virus (RSV) | scheduled | "NCT07653100 (A Phase 3 Study in India to Describe the Safety and Immunogenicity of RSVpreF): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2027-01-25 (ESTIMATED); Lead Sponsor Pfizer." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07653100)) |
| Feb to May 2028 | [Rsvpref vaccine topline data readout](https://sec-api.dev/pdufa/rsvpref-vaccine) | PFE | Respiratory Syncytial Virus (RSV) | scheduled | "NCT07768345 (A Study to Learn About Revaccination With a Vaccine Called RSVpreF in Immunocompromised Adults): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2028-02-02 (ESTIMATED); Lead Sponsor Pfizer." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07768345)) |
| February 2028 | [Rsvpref vaccine primary completion](https://sec-api.dev/pdufa/rsvpref-vaccine) | PFE | Respiratory Syncytial Virus (RSV) | scheduled | "NCT07768345 (A Study to Learn About Revaccination With a Vaccine Called RSVpreF in Immunocompromised Adults): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2028-02-02 (ESTIMATED); Lead Sponsor Pfizer." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07768345)) |
| Feb to May 2029 | [Rsvpref (regimen a) topline data readout](https://sec-api.dev/pdufa/rsvpref-regimen-a) | PFE | Respiratory Syncytial Virus (RSV) | scheduled | "NCT07885956 (A Study to Learn About Revaccination With a Vaccine Called RSVpreF in Older Adults): Overall Status NOT_YET_RECRUITING; Phase PHASE3; Primary Completion 2029-02-07 (ESTIMATED); Lead Sponsor Pfizer." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07885956)) |
| February 2029 | [Rsvpref (regimen a) primary completion](https://sec-api.dev/pdufa/rsvpref-regimen-a) | PFE | Respiratory Syncytial Virus (RSV) | scheduled | "NCT07885956 (A Study to Learn About Revaccination With a Vaccine Called RSVpreF in Older Adults): Overall Status NOT_YET_RECRUITING; Phase PHASE3; Primary Completion 2029-02-07 (ESTIMATED); Lead Sponsor Pfizer." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07885956)) |

## Drugs

- [Respiratory syncytial virus prefusion f subunit vaccine](https://sec-api.dev/pdufa/respiratory-syncytial-virus-prefusion-f-subunit-vaccine) (PFE)
- [Rsvpref](https://sec-api.dev/pdufa/rsvpref) (PFE)
- [Rsvpref vaccine](https://sec-api.dev/pdufa/rsvpref-vaccine) (PFE)
- [Rsvpref (regimen a)](https://sec-api.dev/pdufa/rsvpref-regimen-a) (PFE)

## Feeds and downloads

- Subscribe (iCal): https://sec-api.dev/indications/respiratory-syncytial-virus-rsv.ics
- Next 30 days as CSV: https://sec-api.dev/fda-calendar.csv . JSON: https://sec-api.dev/fda-calendar.json . All events (iCal): https://sec-api.dev/fda-calendar.ics
- New or moved PDUFA dates: https://sec-api.dev/pdufa-dates/feed.xml (RSS), https://sec-api.dev/pdufa-dates/feed.json (JSON Feed)
- FDA approvals: https://sec-api.dev/fda-approvals-today/feed.xml (RSS), https://sec-api.dev/fda-approvals-today/feed.json (JSON Feed)
- License: CC BY 4.0 for the public 30-day window (https://sec-api.dev/biotech/license.txt). Full history: https://sec-api.dev/pricing

## Cite this page

sec-api.dev. "Respiratory Syncytial Virus (RSV) FDA approvals and PDUFA dates." Biotech catalyst calendar, data as of November 16, 2026 (snapshot 20261116T222116Z). https://sec-api.dev/indications/respiratory-syncytial-virus-rsv

```bibtex
@misc{secapidev_indications_respiratory_syncytial_virus_rsv_20261116,
  title        = {Respiratory Syncytial Virus (RSV) FDA approvals and PDUFA dates},
  author       = {{sec-api.dev}},
  year         = {2026},
  month        = {nov},
  howpublished = {\url{https://sec-api.dev/indications/respiratory-syncytial-virus-rsv}},
  note         = {Biotech catalyst calendar, data as of 2026-11-16, snapshot 20261116T222116Z. Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source.}
}
```

```json
{"type":"dataset","id":"secapidev_indications_respiratory_syncytial_virus_rsv_20261116","title":"Respiratory Syncytial Virus (RSV) FDA approvals and PDUFA dates","publisher":"sec-api.dev","URL":"https://sec-api.dev/indications/respiratory-syncytial-virus-rsv","issued":{"date-parts":[[2026,11,16]]},"version":"20261116T222116Z","license":"https://creativecommons.org/licenses/by/4.0/","note":"Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source."}
```

---
Independent. Not affiliated with, endorsed by, or sponsored by the U.S. Food and Drug Administration or the U.S. Securities and Exchange Commission. Dates are as stated by sponsors and FDA; the FDA can act before or after a target date. Not investment advice.
